BUDGET IMPACT ANALYSIS (BIA) OF CABAZITAXEL INTRODUCTION IN TREATMENT OF METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) IN RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Kogon, L. [2 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow, Russia
[2] FGBU NCESMP Minist Hlth Russia, Moscow, Russia
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.640
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A132 / A132
页数：1
相关论文
共 50 条
  • [1] Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer
    Keating, Gillian M.
    DRUGS & AGING, 2013, 30 (05) : 359 - 365
  • [2] Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer
    Gillian M. Keating
    Drugs & Aging, 2013, 30 : 359 - 365
  • [3] SUNITINIB IN COMBINATION WITH DOCETAXEL AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC)
    Zurita, A. J.
    Logothetis, C. J.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Chen, I.
    Chow-Maneval, E.
    George, D. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 198 - 198
  • [4] Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC)
    Zurita, A. J.
    Liu, G.
    Hutson, T.
    Kozloff, M.
    Shore, N.
    Wilding, G.
    Logothetis, C. J.
    Chen, I.
    Maneval, E. Chow
    George, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer
    Malhotra, Manav
    Dhingra, Richa
    Sharma, Tina
    Deep, Aakash
    Narasimhan, Balasubramanian
    Phogat, Priyanka
    Sharma, Prabodh Chander
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2013, 13 (06) : 915 - 920
  • [6] A PHARMACOECONOMIC APRAISAL OF CABAZITAXEL VERSUS ABIRATERONE FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) PROGRESSING AFTER THE TREATMENT WITH DOCETAXEL: A SYSTEMATIC REVIEW
    Bektur, C.
    Nurgozhin, T.
    VALUE IN HEALTH, 2014, 17 (03) : A70 - A70
  • [7] CABAZITAXEL PLUS CORTICOSTEROIDS IN COMPARISON TO CORTICOSTEROIDS ALONE FOR THE TREATMENT OF METASTATIC HORMONE REFRACTORY/CASTRATION-RESISTANT PROSTATE CANCER (MHRPC)
    Schinzel, S.
    Herbold, M.
    Bramlage, P.
    VALUE IN HEALTH, 2012, 15 (07) : A409 - A409
  • [8] Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results
    George, D. J.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Chen, I.
    Maneval, E. Chow
    Logothetis, C. J.
    Zurita, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal
    Kearns, Ben
    Jones, Myfanwy Lloyd
    Stevenson, Matt
    Littlewood, Chris
    PHARMACOECONOMICS, 2013, 31 (06) : 479 - 488
  • [10] IDENTIFICATION OF ANTIBODY RESPONSES INDUCED IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) RECEIVING GVAX IMMUNOTHERAPY FOR PROSTATE CANCER
    Clift, S.
    Harding, T.
    Nguyen, M.
    Koprivnikar, K.
    Huan-Tu, G.
    Sacks, N.
    Small, E.
    Jooss, K.
    JOURNAL OF GENE MEDICINE, 2009, 11 (12): : 1139 - 1140
12345